社区获得性肺炎3种治疗方案的成本-效果分析

目的评价氨苄西林-舒巴坦组（A组）、头孢哌酮组（B组）、左氧氟沙星组（C组）三种方案对治疗社区获得性肺炎药物经济学成本与效果。方法采用回顾性研究方法，运用成本-效果分析法对三种治疗方案进行成本与效果分析。结果三种治疗方案中，A组、B组、C组总成本分别为1770．96元、1896．00元、1153．86元，治愈率分别为46．2％，61．5％，69．2％，每增加1个单位效果A组与B组比C组需多花成本分别为28．49元和52．45元。结论C组为治疗社区获得性肺炎的较佳治疗方案，通过成本-效果分析能优化治疗方案、指导合理用药，提高临床疗效。

Cost-effectiveness analysis of three therapeutic schemes for community acquired pneumonia infections

OBJECTIVE To evaluate the cost-effectiveness of three therapeutic schemes, ampicillin-sulbactam injection(A), cefoperazone injection(B) and levofloxacin injection(C) in treatment of the community acquired pneumonia infections. METHODS Compared the cost and effectiveness of three therapeutic schemes, by using pharmacoeconomic cost-effectiveness analysis of retrospective study. RESULTS The total costs of A,B and C schemes were RMB 1770.96,1896.00 and 1153.86 yuans, respectively, and the effective ratios were 46.2%,61.5% and 67.2%,respectively. An increase of 1% effective rate in group C saved RMB 28.49 and 52.45 yuans in comparison with that in group A and B. CONCLUSION According to the evalution with pharmacoeconomic cost-effectiveness analysis, the group C is the best one for treating the community acquired pneumonia infection. The cost-(effective) analysis play an important role in optimizing therapeutic scheme, guiding rational use of drug and rising effective.